Prospective Study on the Use of Transdermal Analgesic Buprenorphine Patches for Chronic Pain in the UK
CompletedNCT01225861
View the official record on ClinicalTrials.gov Recruiting status changes often. Contact the study team listed on ClinicalTrials.gov, and talk to your doctor before joining a study.
This study has no listed site in Canada in this snapshot. It is included as part of the worldwide chronic pain corpus.
Brief summary (from the registry)
The primary objective of the study is the descriptive analysis of incidence \& severity of side effects \& reasons for discontinuation of the treatment of chronic pain with transdermal analgesic Buprenorphine patches.
Study details
- Conditions
- Sponsor
- Mundipharma Research Limited
- Start date
- 2010-11
- Primary completion
- 2013-08
- Sex
- All
- Age range
- from 18 Years
- Results posted
- No results posted in this snapshot
- Countries
- United Kingdom
- Total sites listed
- 1
Eligibility criteria
Show eligibility criteria (verbatim from the registry)
Inclusion Criteria * Patient age \> 18 * Patient is treated with transdermal Buprenorphine * The patient is able to answer the patient's survey \& has an estimated overall survival of minimum 6 months * The patient gives his/her informed, written consent to participate in the study Exclusion Criteria * Patient Age \< 18 * Patient has less than 6 months survival expectancy * Patient is unable to answer the patient survey for whatever reason in any feasible form
Source: ClinicalTrials.gov (US National Library of Medicine), snapshot October 2026. Check the registry for current recruiting status. Record: https://clinicaltrials.gov/study/NCT01225861